We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$810M
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+21.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$631M
AUM Growth
+$110M
(+21%)
Cap. Flow
+$37M
Cap. Flow
% of AUM
5.86%
Top 10 Holdings %
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$17M |
| 2 |
Glaukos
GKOS
|
+$9.15M |
| 3 |
Biogen
BIIB
|
+$9.05M |
| 4 |
ELGX
Endologix Inc
ELGX
|
+$6.78M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$6.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$13.1M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$11.1M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$5.44M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$4.39M |
| 5 |
Centene
CNC
|
+$4.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92% |
| 2 | Financials | 1.18% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.12% |
| 5 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
101
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $260K | 0.04% |
50,000
| – | – |
|
|
MTEM
102
DELISTED
Molecular Templates, Inc.
MTEM
| $115K | 0.02% |
1,221
| – | – |
|
|
ISEE
103
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $88K | 0.01% |
23,920
| – | – |
|
|
ANTH
104
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $85K | 0.01% |
25,000
| – | – |
|
105
Caterpillar
CAT
$387B
| – | – |
-1,548
| Closed | -$144K |
|
106
Illumina
ILMN
$28.4B
| – | – |
-15,420
| Closed | -$1.92M |
|
107
LivaNova
LIVN
$4.2B
| – | – |
-80,000
| Closed | -$3.6M |
|
108
Pediatrix Medical
MD
$2.2B
| – | – |
-9,000
| Closed | -$600K |
|
109
Perrigo
PRGO
$1.78B
| – | – |
-25,000
| Closed | -$2.08M |
|
|
110
Teva Pharmaceuticals
TEVA
$41.2B
| – | – |
-360,000
| Closed | -$13.1M |
|
|
ZLTQ
111
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| – | – |
-125,000
| Closed | -$5.44M |
|
|
ARIA
112
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-895,000
| Closed | -$11.1M |
|
|
NDRM
113
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| – | – |
-142,546
| Closed | -$3.17M |
|
Similar funds
PS
ACM
AR
KCP
BCM
RIM
GCM
CL
Rhenman & Partners Asset Management's Q1 2017 Portfolio in Review
As of Q1 2017, Rhenman & Partners Asset Management held 113 positions worth $631M, up 21% from $522M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Rhenman & Partners Asset Management deployed $37M of net new capital in Q1 2017, opening 5 new positions and adding to 44 existing holdings. Its largest new stake was Abbott: 115,000 shares worth $5.11M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $4.39M trimmed.
- Rhenman & Partners Asset Management's largest Q1 2017 buy was Abbott: 115,000 shares worth $5.11M.
- Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $17M increase.
- Rhenman & Partners Asset Management's biggest Q1 2017 reduction was Bristol-Myers Squibb, cutting an estimated $4.39M.
- Rhenman & Partners Asset Management fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $13.1M.
- Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $631M portfolio in Q1 2017.
- Rhenman & Partners Asset Management opened 5 new positions and closed 9 in Q1 2017.
- Rhenman & Partners Asset Management's portfolio value rose 21% quarter-over-quarter to $631M.
Based on Rhenman & Partners Asset Management's 13F filing for Q1 2017, filed 19 Apr 2017.